hit counter
ANI Pharmaceuticals, Inc. (ANIP) Stock News Sentiment & Price - Sentifly
ANIP - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ANI Pharmaceuticals, Inc. (ANIP)

USA
Biotechnology
NASDAQ
ANIP Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ANIP Latest news
Business Wire
Neutral
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
2021-11-11 06:50

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma. The divestitures required by the FTC of development rights to one generic drug and assets with respect to another generic drug are immaterial to the Company's business. The acceptance by the FTC satisfies all required antitr

Business Wire
Neutral
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
2021-11-08 16:05

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering. A total of 1,500,000 shares of its common stock were sold at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are $75 million, before deducting the underwriting discounts and commissions and offering expenses. In addition, ANI granted the underwriters a 30-day option to

Business Wire
Neutral
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
2021-11-03 22:54

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI” or the "Company") today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are expected to be $75 million, before deducting the underwriting discounts and commissions and other offering expenses. In addition, ANI granted the underwriters a 30-day option to purchase up to a

Business Wire
Neutral
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2021-11-03 16:03

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, ANI intends to grant the underwriters a 3

Invezz
Positive
ANI Pharmaceuticals reports 3rd Quarter financial results as shares surges
2021-11-01 14:10

ANI Pharmaceuticals (NASDAQ: ANIP) recently announced that it recorded $52.1 million net revenues for its third quarter of 2021. However, this was roughly one million dollars less than what they reported in the same quarter of the previous fiscal year.

The Motley Fool
Positive
Here's Why Ani Pharmaceuticals Stock Is Rocketing Higher Today
2021-11-01 12:36

The company reported positive third-quarter earnings, and the FDA granted approval for its generic version of Acthar Gel.

Seeking Alpha
Neutral
ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q3 2021 Results - Earnings Call Transcript
2021-11-01 12:26

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
2021-11-01 09:12

ANI (ANIP) delivered earnings and revenue surprises of 42.25% and 3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
ANI Pharmaceuticals Reports Third Quarter 2021 Results
2021-11-01 06:45

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended September 30, 2021. Third Quarter and Recent Business Highlights: The U.S. Food and Drug Administration (FDA) approved the Company's supplemental new drug application (sNDA) for Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) (Cortrophin Gel) for the treatment of certain chronic autoimmune disorders

Business Wire
Neutral
ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
2021-11-01 06:30

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) (Cortrophin Gel) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), in addition to excess urinary protei

Loading more news...